Revolutionizing mRNA for Life
Forward Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the "company") contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potency efficacy of the company’s vaccine candidate and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” "intend," "believe," "estimate," "plan,” “seek,” “project,” or "expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
CureVac at a Glance

**Pioneers in Medical mRNA Applications**
- Founded in 2000
- Headquartered in Tübingen
- >550 employees
- Nasdaq listed

**Unique mRNA Technology**
- Unmodified mRNA
- Balanced immune activation
- Low dose activity

**Deep Clinical Pipeline**
- Prophylactic Vaccines
- Immuno-oncology
- Protein Therapies

**Manufacturing Expertise**
- 3 GMP suites online
- 1 large-scale suite in progress
- Broad European CMO network
- Flexible and mobile GMP units

**Strategic Partnerships**
- Development support
- Medical affairs expertise
- Commercial execution power
## FOCUS AREA

### Prophylactic Vaccines
- Induction of antibody responses
- Induction of T-cell responses

### Oncology
- Induction of T-cell responses
- Induction of antibody responses
- Breaking of tolerance
- Activation of innate and adaptive immunity

### Protein Therapy
- Oncology
  - Use of the liver as a bioreactor
  - Convey controlled immunogenicity
- Rare Diseases
  - Ocular administration
  - Mucosal delivery
  - Other

## LEAD PROGRAM / COLLABORATION

<table>
<thead>
<tr>
<th>Program/Collaboration</th>
<th>Formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 CVnCoV</td>
<td>Lipid nano-particle</td>
</tr>
<tr>
<td>Rabies CV7202</td>
<td>Lipid nano-particle</td>
</tr>
<tr>
<td>Tumor-associated antigens</td>
<td>Peptide based</td>
</tr>
<tr>
<td>Shared neo-antigens</td>
<td>CV8102</td>
</tr>
<tr>
<td>Genmab collaboration</td>
<td>Lipid nano-particle</td>
</tr>
<tr>
<td>Harvard collaboration</td>
<td>Polymer based</td>
</tr>
<tr>
<td>Yale collaboration</td>
<td>Lipid nano-particle</td>
</tr>
<tr>
<td>CRISPR collaboration</td>
<td></td>
</tr>
</tbody>
</table>
# CureVac Pipeline: A Diversified Portfolio

<table>
<thead>
<tr>
<th>AREA</th>
<th>PROGRAMS AND INDICATIONS</th>
<th>COLLABORATIONS</th>
<th>PRE-CLINICAL DISCOVERY</th>
<th>PRE-CLINICAL DEVELOPMENT</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROPHYLACTIC VACCINES</td>
<td>CVnCoV: COVID-19</td>
<td>CEPI (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CV7202: Rabies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disruptive low dose technology</td>
<td>Lassa, Yellow Fever</td>
<td>CEPI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Respirational Syncytial Virus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other Infectious Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diverse projects (Rota, Malaria, Universal Influenza)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ONCOLOGY</td>
<td>CV8102: cMEL, ACC, SCC, HNSCC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccines and intra-tumoral applications</td>
<td>BI13618409 (CV9202): Non-Small Cell Lung Cancer</td>
<td>Boehringer Ingelheim</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shared neo-antigen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tumor Associated Antigens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROTEIN THERAPY</td>
<td>Cas9 Gene-editing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rare diseases, gene editing &amp; antibodies</td>
<td>Ocular Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lung Respiratory Diseases</td>
<td>Yale</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Therapeutic Antibodies</td>
<td>Genmab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(1) CEPI early stage Phase 1 clinical trial funding  
cMEL: Cutaneous melanoma; ACC: Adenoid cystic carcinoma; SCC: Squamous cell carcinoma; HNSCC: Squamous cell carcinoma of head and neck
2020 – Year of Corporate Transformation

COVID-19 PROGRAM
- Rigorous pre-clinical candidate selection
- Accelerated clinical development in Phase 1, 2, 3
- Manufacturing optimization and scale-up

BUSINESS EVOLUTION
- Growing talent base: >550 employees
- Management expertise expansion
- Strategic partnership

FINANCIAL EXECUTION
- CVAC | Nasdaq Listed
- Strong cash position: ~$1.04 billion*

*CureVac Investor Handout, January 2021
*As of September 30, 2020
EC: European Commission
Our Core Mandate 2021: Deliver a Safe and Effective COVID-19 Vaccine

Succeeding in the clinic
- Expect to provide first efficacy data in Q1 2021
- Expect to gain regulatory approval in Q2 2021

Creating capacity
- 3 in-house GMP certified suites
- 4th large-scale suite in progress
- Trans-European CMO network

Delivering the vaccine
- Bayer adding key operational and commercial support
- Cross-border and cross-institution collaborations
# Executing on Corporate Growth With An Experienced Team

## CureVac Management

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Franz-Werner Haas</td>
<td>Chief Executive Officer (LLD, LLM)</td>
</tr>
<tr>
<td>Pierre Kemula</td>
<td>Chief Financial Officer (B.Sc.)</td>
</tr>
<tr>
<td>Mariola Fotin-Mleczek</td>
<td>Chief Technology Officer (PhD)</td>
</tr>
<tr>
<td>Florian von der Mülbe</td>
<td>Chief Production Officer (PhD, MBA)</td>
</tr>
<tr>
<td>Bernd Winterhalter,</td>
<td>Interim Chief Development Officer (MD, PhD)</td>
</tr>
<tr>
<td>Igor Splawski</td>
<td>Chief Scientific Officer (PhD)</td>
</tr>
<tr>
<td>Antony Blanc,</td>
<td>Chief Business/Commercial Officer (PhD)</td>
</tr>
</tbody>
</table>

NEW: Added 2021
UNIQUE MECHANISM OF ACTION
- Unmodified, natural mRNA
- Inducing type I interferons
- Inducing B and T cell responses
- Activating innate immune system
- Inducing boostable memory responses

PROPHYLACTIC VACCINES
- Active at low dose in humans
- Enables multivalent vaccines
- Fast, large-scale GMP production
- Multiple product candidates

CANCER VACCINES & IMMUNO-MODULATION
- Innate and adaptive immune activation
- Key activation of T cell responses
- Demonstrated breaking of tolerance
- Multiple product candidates
Unmodified mRNA: Differentiated Mode of Action, Mimics Natural Immunity

- Optimizing untranslated regions based on potent, tissue-specific regulatory elements
- Optimizations allow for increased translation efficiency and immunogenicity
- Maximizing ribosome interaction for increased protein expression enables low dose activity

Diagram:
- Encoded protein
- Ribosomes
- Targeted optimizations
- mRNA construct
- 5’ untranslated region
- Open Reading Frame
- Protein coding portion
- 3’ untranslated region
- Optimized ribosome interaction
Prophylactic Vaccines: COVID-19 vaccine candidate, CVnCoV
Non-Human Primate Data Suggests CVnCoV Protection Against SARS-CoV-2

Humoral and cellular responses following vaccination with 8µg

- **Strong antibody induction**
  - High titers of Spike (1.6 $10^3$) and RBD (3.2 $10^3$) binding antibodies
  - High titer of virus neutralizing antibodies (2.7 $10^4$ at peak)
- Generation of **multiclonal T cell responses** in line with previous mouse data
- Dose efficiency comparable to 12 µg dose advanced into late-stage human clinical testing

SARS-CoV-2 challenge infection following vaccination with 8µg

**UPPER RESPIRATORY TRACT: NOSE AND THROAT**
- **Reduced** viral load

**LOWER RESPIRATORY TRACT: LUNGS**
- **Full lung protection**, no detectable viruses

*Full manuscript of pre-clinical data available on bioRxiv pre-print server*
Clinical Development of COVID-19 Vaccine Candidate, CVnCoV

DOSE ESCALATION TRIAL
- 2-20µg, placebo controlled
- 280 participants, **fully recruited**
- Expected data update: **Q1 2021**

DOSE CONFIRMATION TRIAL
- 6µg / 12µg, placebo controlled
- 690 participants, **fully recruited**
- Expected first data: **Q1 2021**

SAFETY AND EFFICACY TRIAL
- 12µg, placebo controlled
- >37,000 participants, **recruiting**
- Expected interim data: **Q1 2021**
**CVnCoV: SARS-CoV-2 Specific Antibody Responses**

---

**Spike protein binding antibodies**

- Induction of antibodies across tested dose range
- Immune responses detected at lowest dose of 2µg

**Virus neutralizing antibodies**

- Antibody titers reach highly medically relevant HCS level at 12µg
  - HCS: Comparator with highest medical relevance
  - 51 patients with multiple symptoms, 16 hospitalized
  - Antibodies measured at peak times

---

*CureVac Investor Handout, January 2021*
Quality of immune response is reflected in antibody ratios, which are similar in CVnCoV-vaccinated subjects and convalescent patients.

<table>
<thead>
<tr>
<th>Antibody Type</th>
<th>CVnCoV-vaccinated</th>
<th>Virus-infected</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPIKE antibodies</td>
<td>Neutralizing = Binding</td>
<td>1.0</td>
</tr>
<tr>
<td>RBD antibodies</td>
<td>Neutralizing = Binding</td>
<td>1.0</td>
</tr>
</tbody>
</table>
Keeping Ahead of SARS-CoV-2 Evolution and Occurrence of New Mutations

- Neutralizing capability of induced antibodies toward mutated virus
- Test via exposing blood serum of trial participants to mutated virus
- Testing at partner labs ongoing with clinical trial blood samples

In vitro testing of CVnCoV efficacy toward mutated virus

CureVac scientific task force continuously monitors occurrence of SARS-CoV-2 mutations

- Monitoring of all available scientific data on mutation
- Computes structural impact of mutations on antibody binding sites
- Screening allows for first indication of potential severity of mutation

Bioinformatic pre-screening of CVnCoV efficacy toward mutated virus
Scaling-up internal and external manufacturing capacities

<table>
<thead>
<tr>
<th>GMP I</th>
<th>GMP II</th>
<th>GMP III</th>
<th>European CMO network</th>
</tr>
</thead>
<tbody>
<tr>
<td>online</td>
<td>online</td>
<td>online</td>
<td>▪ Highly experienced CMO partners for key manufacturing steps</td>
</tr>
<tr>
<td>Phase I/II</td>
<td>Phase I/II</td>
<td>Phase III Initial market supply</td>
<td>▪ Flexible network to serve pandemic demand, mitigating supply chain risks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Expected annual network output: up to 300m doses in 2021 up to 600m doses in 2022</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GMP IV</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>expected H2 2022</td>
</tr>
<tr>
<td></td>
<td>Large-scale market supply</td>
</tr>
</tbody>
</table>
RNA Printer™: Mobile Manufacturing Expected to Revolutionize GMP Process

Cloud based network
Rapid exchange of insights

GLOBAL HEALTH

PANDEMIC PREPAREDNESS in hospitals in outbreak regions
- Containing an outbreak at its origin with 1-3g output per week

HEALTHCARE

CUSTOMIZED, POINT OF CARE mRNA therapeutics
- Expected to rapidly provide therapeutics tailored to patients’ needs

RESEARCH

CLINICAL DEVELOPMENT ACCELERATION at lower costs
- Realizing different constructs and supplying studies onsite
Delivering the Vaccine: CureVac and Bayer Join Forces on CVnCoV

**Expertise and infrastructure**
- Adding operational knowledge, broad international reach and regional access to support global supply of CVnCoV

**Support of product development**
- Adding muscle in areas such as clinical operations, regulatory affairs, pharmacovigilance, and supply chain performance

**Key territory operations**
- Adding country support for EU member states, Norway, Iceland, Liechtenstein, UK, Switzerland
- CureVac to be Market Authorization Holder, option for Bayer in other markets outside the EU

**Differentiated mRNA technology**

**COVID-19 lead program, CVnCoV**

**Manufacturing capacity**
CVnCoV Shelf Life Allows for Established Cold-Chain Distribution

-80°C → 5°C → 5°C → 5°C → Room temp.

- 5°C (41°F) SHELF LIFE OF AT LEAST 3 MONTHS*
- FOR 24 HOURS*

- Facilitated logistics for decentralized storage and large-scale vaccination efforts
- Expected positive impact on distribution, cost and waste compared to ultra-low cold chain requirements

*Stability studies for CVnCoV are ongoing; results may change materially.
Key Agreement with European Commission

Delivering up to 405 million doses of CVnCoV to European member states

- Agreement for 225m doses and an additional 180m dose option
- Upfront payment expected to mitigate project costs and help to de-risk production before regulatory approval
- Leveraging in-house manufacturing as well as integrated European manufacturing network
Oncology: Solid Tumor lead program, CV8102
**UNIQUE MECHANISM OF ACTION**

- Unmodified, natural mRNA
- Inducing type I interferons
- Inducing B and T cell responses
- Activating innate immune system
- Inducing boostable memory responses

**PROPHYLACTIC VACCINES**

- Active at **low dose** in humans
- Enables **multivalent** vaccines
- Fast, **large-scale** GMP production
- Multiple product candidates

**CANCER VACCINES & INTRA-TUMORAL IMMUNOMODULATION**

- **Innate** and **adaptive** immune activation
- Key activation of **T cell responses**
- Demonstrated **breaking of tolerance**
- Multiple product candidates
CV8102: From Local Immune Activation to Systemic Immune Responses

CV8102 targets immune receptors TLR 7, TLR8 and RIG-I

TREATED TUMOR LESION
- Induction of cytokines, chemokines
- Antigen release and presentation
- Activation of innate immune cells
- NK and T-cell activation
- Tumor growth inhibition

DRAINING LYMPH NODE
- Activation of immune cells
- Antigen presentation, T cell priming
- NK, T- and B-cell activation

DISTAL TUMORS
- Tumor growth inhibition
- Amplification of immune response

NK cells: Natural killer cells
Preliminary data on overall tumor response and duration (data cut-off October 5, 2020)

- **Preliminary efficacy: combination with PD-1 antibodies**
  - 1 Partial Response (cMel)
  - 2 Stable Diseases (cMel, HNSCC)
  - 3 Stable Diseases with shrinkage of injected and/or non-injected lesions* (HNSCC, Melanoma, cSCC)

- **Preliminary efficacy: single agent**
  - 1 Complete Response (cMel)
  - 2 Partial Responses (cMel, cSCC)

- **55% pts anti-PD-1 pre-treated**
- **7% with anti-CTLA4**

- **86% pts anti-PD-1 pre-treated**
- **48% pts with anti-CTLA4**

---

cMEL: Cutaneous melanoma; ACC: Adenoidcystic carcinoma; SCC: Squamous cell carcinoma; HNSCC: Squamous cell carcinoma of head and neck

CureVac Investor Handout, January 2021
74-year-old female patient, stage IIIc melanoma with multifocal in-transit metastases
- CR of injected and non-injected cutaneous lesions
- CR of subcutaneous lesion (MRI)
- Marked transient rise in serum IL-6 and CRP following the first intra-tumoral injection
- Partial regression of injected tumor lesion after 5 injections
- CR of in-transit metastases on MRI, CR of all skin metastases at week 12
- Patient continued to receive injections at monthly intervals for 9 months without recurrence

91-year-old male patient, stage IV HNSCC with large buccal and small lip lesion and a contralateral cervical metastatic LN, pretreated with cetuximab, external beam radiation and multiple surgeries
- Buccal and lip lesions remained stable for 9 months (study duration)
- Untreated metastatic LN showed ongoing regression
- Overall stable disease according to RECIST 1.1 for 9 months
- Early increase in IL-6

50-year-old female patient, patient with anti-PD-1 refractory melanoma, stage IV N3c M1b at study entry, early progression on adjuvant Nivolumab treatment
- After 8 IT injections of CV8102
  - PR per RECIST 1.1 with shrinkage of injected and several non-injected lesions

---

**Case study 1**
150 µg Complete Response (CR)

**Case study 2**
100 µg CV8102 (SD)

**Case study 3**
450 µg CV8102 (PR)
Financial Overview
Q3 and First Nine Months of 2020
Our Financial Strength Enables the Company Transformation

Nasdaq listing: 
~€193 million

€252 million
Grant of the German Federal Ministry of Education and Research

€75 million
European Investment Bank (EIB)

Cash position 
~$1.04bn*

Private Round: 
~€560 million

GSK 
€150 million
GSK Upfront 
€120 million

KfW 
€300 million

Cumulative Investments 
€110 Mio

Upfront Payment 
European Commission

*As of September 30, 2020
On track to finalize late stage clinical CVnCoV development

Positioned to bring CVnCoV to market in H1 2021

Broaden operational infrastructure along CVnCoV momentum

Focused pipeline strategy in our three key areas

Grow the talent base for transformation from biotech to biopharma
Appendix
## Financial Results for Q3 and first Nine Months 2020

<table>
<thead>
<tr>
<th></th>
<th>Three Months ended September 30</th>
<th>Nine Months ended September 30</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2020</td>
<td>2019</td>
</tr>
<tr>
<td></td>
<td>unaudited</td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>5.162</td>
<td>1.096</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>-1.973</td>
<td>-6.999</td>
</tr>
<tr>
<td>Selling and distribution expenses</td>
<td>200</td>
<td>24</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>-34.570</td>
<td>-5.349</td>
</tr>
<tr>
<td>Other operating income</td>
<td>3.964</td>
<td>1.333</td>
</tr>
<tr>
<td>Other operating expenses</td>
<td>-119</td>
<td>-126</td>
</tr>
<tr>
<td><strong>Operating loss</strong></td>
<td><strong>-36.758</strong></td>
<td><strong>-19.145</strong></td>
</tr>
<tr>
<td>Financial result</td>
<td>-68</td>
<td>141</td>
</tr>
<tr>
<td><strong>Loss before income tax</strong></td>
<td><strong>-36.690</strong></td>
<td><strong>-19.004</strong></td>
</tr>
<tr>
<td>Income tax benefit/ (expenses)</td>
<td>-144</td>
<td>644</td>
</tr>
<tr>
<td><strong>Net loss for the period</strong></td>
<td><strong>-36.834</strong></td>
<td><strong>-18.360</strong></td>
</tr>
<tr>
<td>Diluted earnings per share (In € per share)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### CVnCoV Phase 1 Trial Design

- Partially blinded, placebo-controlled, dose-escalation study in healthy adults (18-60 years)
- Clinical sites in Germany and Belgium
- Intra-muscular vaccinations on day 1 and 29
- Data Safety Monitoring Board (DSMB) approval of tolerability and dose escalation

#### CVnCoV Phase 1 Trial Design Table

<table>
<thead>
<tr>
<th>Dose Level</th>
<th>Seronegative</th>
<th>Seropositive</th>
<th>Fully Recruited</th>
</tr>
</thead>
<tbody>
<tr>
<td>12µg</td>
<td>12µg</td>
<td>Sentinel group (11)</td>
<td>24</td>
</tr>
<tr>
<td>8µg</td>
<td>8µg</td>
<td>Full cohort</td>
<td>46</td>
</tr>
<tr>
<td>6µg</td>
<td>6µg</td>
<td>/</td>
<td>46</td>
</tr>
<tr>
<td>4µg</td>
<td>4µg</td>
<td>/</td>
<td>46</td>
</tr>
<tr>
<td>2µg</td>
<td>2µg</td>
<td>Full cohort</td>
<td>46</td>
</tr>
</tbody>
</table>

- **Day 1**: Prime vaccination
- **Day 29**: Boost vaccination
- **Reported here**: Day 36 & 43
- **Total**: 220
- **Total**: 41

CureVac Investor Handout, January 2021
No serious adverse events or dose limitations were observed. All symptoms were transient and resolved rapidly within 24 to 48 hours.
Analysis of SARS-CoV-2 Specific Antibody Responses

**Binding antibodies:**
- Measured by ELISA
- Spike protein (S1+S2)
- Receptor Binding Domaine (RBD)

**Virus neutralizing antibodies:**
- Measured by micro-neutralization assay
- Live human SARS-CoV-2 virus
- Positive titers by 50% of neutralization

**Human Convalescent Sera (HCS) panel:**
- Comparator with highest medical relevance
- 51 patients with multiple symptoms, 16 hospitalized
- Antibodies measured at the peak time
CVnCoV Phase 1 Spike Binding Antibodies: Show dose-dependent induction

- Dose-dependent induction of binding antibodies across tested dose range
- Immune response detected at lowest dose of 2µg
- Binding antibody titers reach highly medically relevant HCS level at 12µg
CVnCoV Phase 1 Neutralizing Antibodies: Reach highest relevant HCS level

- Titers remain stable after reaching peak level
- Immune response already at lowest dose of 2µg detected
- Neutralizing antibody titers reach highly medically relevant HCS level at 12µg

MN titers: Micro-neutralization titers; HCS: Human convalescent sera
Unique Mechanism of Action Mediated by Interferon Type 1

In animal models…

Rat model
Day 1 after 1 dose

Dose dependent induction of IFN-α in rats

Mouse model
Day 15 after 2nd dose

…and in humans

Induction of IFN-α (all subjects)

Day 1 after 1 dose

Dose dependent induction of SARS-CoV-2 specific CD8+ T cells

Induction of SARS-CoV-2 specific CD4+ T cells

Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

CureVac Investor Handout, January 2021
Long-lasting booster effect of neutralizing SARS-CoV-2 antibodies induced with 2µg CVnCoV in seropositive subjects

- CVnCoV vaccine was well tolerated in seropositive subjects
- All seropositive subjects benefited from the vaccination
- Stable antibody titers imply induction of immune memory for long-term protection